metoprolol and Cardiac Remodeling, Ventricular studies

Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this prospective, randomized study was to investigate the effect of pretreatment with two different intracellular calcium-lowering drugs (verapamil and metoprolol) on recovery from atrial effective refractory period (AERP) shortening after internal electrical cardioversion (EC) of persistent atrial fibrillation (AF) in patients on amiodarone."	9.10	Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. ( Bertaglia, E; D'Este, D; Michieletto, M; Pascotto, P; Zerbo, F, 2003)
"The pre-treatment plasma level of ANP may be a predictor of LV antiremodelling from treatment with metoprolol in patients with chronic heart failure."	9.10	Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002)
"In this randomized, placebo-controlled and double-blind substudy to the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF), 41 patients were examined with magnetic resonance imaging three times in a six-month period, assessing LV dimensions and function."	9.09	Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Larsson, HB; Nilsson, JC; Sondergaard, L, 2000)
"Metoprolol protects against chronic OSA-induced cardiac apoptosis and fibrosis in left ventricular myocytes of canines, which may provide new potential strategy for drug therapy of OSA."	7.81	Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. ( Ding, X; Li, H; Li, W; Li, Y; Liu, L; Liu, Z; Peng, W; Wang, D; Yan, S; Zhang, S; Zhao, J, 2015)
"In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks."	7.79	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. ( Babick, A; Dhalla, NS; Elimban, V; Zieroth, S, 2013)
"Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)."	7.74	Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008)
"Metoprolol reduces post-MI ventricular arrhythmias, partly by altering the neural remodeling process."	7.74	Effects of prolonged metoprolol treatment on neural remodeling and inducible ventricular arrhythmias after myocardial infarction in rabbits. ( Cheng, WJ; Hu, HS; Shi, CW; Wang, Q; Wang, XL; Xing, QC; Xue, M; Yan, SH, 2007)
"Metoprolol succinate was given to 60 patients with class I-III heart failure and ejection fraction <45% after myocardial infarction."	7.72	[Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure]. ( Churganova, LIu; Gavril'eva, SA; Ivanov, GG; Poltavskaia, MG; Sheianov, MV; Shumilova, KM; Syrkin, AL, 2003)
"To compare the effects of carvedilol and metoprolol in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats."	7.71	[Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, JL; Chen, ZJ; Gao, RL; Lu, SQ; Ruan, YM; Sun, RC; Tang, YD; Wang, PH; Yang, YJ; Zhang, P, 2001)
"Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)."	7.71	Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002)
"Metoprolol treatment for 2 weeks improved LV systolic function."	5.35	Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009)
"The aim of this prospective, randomized study was to investigate the effect of pretreatment with two different intracellular calcium-lowering drugs (verapamil and metoprolol) on recovery from atrial effective refractory period (AERP) shortening after internal electrical cardioversion (EC) of persistent atrial fibrillation (AF) in patients on amiodarone."	5.10	Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. ( Bertaglia, E; D'Este, D; Michieletto, M; Pascotto, P; Zerbo, F, 2003)
"The pre-treatment plasma level of ANP may be a predictor of LV antiremodelling from treatment with metoprolol in patients with chronic heart failure."	5.10	Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Kjaer, A; Larsson, HB; Nilsson, JC; Sondergaard, L, 2002)
"In this randomized, placebo-controlled and double-blind substudy to the Metoprolol CR/XL Randomized Intervention Trial in Heart Failure (MERIT-HF), 41 patients were examined with magnetic resonance imaging three times in a six-month period, assessing LV dimensions and function."	5.09	Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. ( Fritz-Hansen, T; Groenning, BA; Hildebrandt, PR; Larsson, HB; Nilsson, JC; Sondergaard, L, 2000)
"The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2 -adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1 -adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF)."	3.81	Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. ( Calzetta, L; Capuano, A; Donniacuo, M; Gritti, G; Martuscelli, E; Matera, MG; Orlandi, A; Rafaniello, C; Rinaldi, B; Rossi, F; Sodano, L, 2015)
"Metoprolol protects against chronic OSA-induced cardiac apoptosis and fibrosis in left ventricular myocytes of canines, which may provide new potential strategy for drug therapy of OSA."	3.81	Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. ( Ding, X; Li, H; Li, W; Li, Y; Liu, L; Liu, Z; Peng, W; Wang, D; Yan, S; Zhang, S; Zhao, J, 2015)
"Clenbuterol (Cl), a β2 agonist, is associated with enhanced myocardial recovery during left ventricular assist device (LVAD) support, and exerts beneficial remodelling effects during mechanical unloading (MU) in rodent heart failure (HF)."	3.80	Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading. ( Gandhi, A; Ibrahim, M; Kukadia, P; Navaratnarajah, M; Shah, A; Siedlecka, U; Soppa, G; Terracciano, CM; van Doorn, C; Yacoub, MH, 2014)
"The effects of metoprolol or/and BNP were studied on cardiac remodelling, excitation-contraction coupling and arrhythmias in an experimental mouse model of ischaemic heart failure following postmyocardial infarction."	3.80	Β-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure? ( Aimond, F; Babuty, D; Cassan, C; Fauconnier, J; Gac, A; Karam, S; Lacampagne, A; Le Guennec, JY; Richard, S; Roberge, S; Roussel, J; Thireau, J, 2014)
"In order to examine the reversibility of heart failure due to myocardial infarction (MI) by β-adrenoceptor blockade, 12 weeks infarcted rats were treated with or without metoprolol (50 mg/kg/day) for 8 weeks."	3.79	Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. ( Babick, A; Dhalla, NS; Elimban, V; Zieroth, S, 2013)
"Ivabradine (Iva) has shown beneficial structural and functional effects in clinical and experimental heart failure (HF), but its action in combination with mechanical unloading (MU), such as during treatment with left ventricular assist devices (LVAD), is unknown."	3.79	Influence of ivabradine on reverse remodelling during mechanical unloading. ( Dias, P; Gandhi, A; Ibrahim, M; Navaratnarajah, M; Sarathchandra, P; Shah, A; Siedlecka, U; Terracciano, CM; van Doorn, C; Yacoub, MH, 2013)
"Chronic treatment with ketamine caused significant ventricular myocardial apoptosis, fibrosis and sympathetic sprouting, which altered the electrophysiological properties of the heart and increased its susceptibility to malignant arrhythmia that may lead to sudden cardiac death."	3.78	Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. ( Dong, DL; Geng, JQ; Gong, YT; Gong, ZH; Han, CL; Li, WM; Li, Y; Liu, GZ; Liu, L; Pan, ZW; Sheng, L; Shi, J; Sun, DH; Tan, XY; Yang, BF, 2012)
"To investigate whether heart rate reduction via I(f)-channel blockade and β-receptor blockade prevents left ventricular (LV) dysfunction, we studied ivabradine and metoprolol in angiotensin II-induced heart failure."	3.78	Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. ( Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C, 2012)
" The aim of the present study was to investigate the prevalence of hypertension in patients with dilated cardiomyopathy (DCM) and to determine the tolerance and efficacy of a high dose of the β1-adrenoceptor antagonist metoprolol in the long-term treatment of DCM patients."	3.75	Dilated cardiomyopathy with hypertension: prevalence and response to high-dose β1-adrenoceptor antagonist therapy. ( Chen, S; Chen, Y; Wang, J; Yang, T; Zheng, X, 2009)
" Carvedilol is more effective than Metoprolol for improving the hemodynamics and in attenuating ventricular remodeling after heart failure."	3.74	Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. ( Chen, GW; Jiang, ZF; Lin, Y; Wang, LX; Wu, TG; Zhao, Q, 2007)
"Acute intravenous infusion of ranolazine (Ran), an anti-ischemic/antiangina drug, was previously shown to improve left ventricular (LV) ejection fraction (EF) without a concomitant increase in myocardial oxygen consumption in dogs with chronic heart failure (HF)."	3.74	Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. ( Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008)
"Metoprolol reduces post-MI ventricular arrhythmias, partly by altering the neural remodeling process."	3.74	Effects of prolonged metoprolol treatment on neural remodeling and inducible ventricular arrhythmias after myocardial infarction in rabbits. ( Cheng, WJ; Hu, HS; Shi, CW; Wang, Q; Wang, XL; Xing, QC; Xue, M; Yan, SH, 2007)
" We aimed to verify whether the beta-blocker, metoprolol, and the pure heart-rate-reducing agent, ivabradine, have the same effects on haemodynamic function, ventricular remodeling, and Ca2+ handling in post-myocardial infarction (MI) heart failure in rat."	3.74	Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. ( Mackiewicz, U; Maczewski, M, 2008)
" Here, we show that blockade of beta-adrenoceptors directly in the brain (chronic intracerebroventricular administration of metoprolol) attenuates the progression of left ventricular remodeling in a rat model of myocardial infarction-induced heart failure."	3.74	Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. ( Bondar, SI; Gourine, A; Gourine, AV; Spyer, KM, 2008)
"We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group)."	3.73	Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. ( Hu, SJ; Hu, Y; Sun, YL; Wang, LH; Zhou, JY, 2005)
"The dose-related beneficial effects of carvedilol on survival in heart failure have been verified, however, the effects on left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) have not been defined."	3.72	Comparison of metoprolol with low, middle and high doses of carvedilol in prevention of postinfarction left ventricular remodeling in rats. ( Chen, J; Chen, Z; Gao, R; Ruan, Y; Tang, Y; Wang, Y; Yang, Y, 2003)
"Metoprolol succinate was given to 60 patients with class I-III heart failure and ejection fraction <45% after myocardial infarction."	3.72	[Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure]. ( Churganova, LIu; Gavril'eva, SA; Ivanov, GG; Poltavskaia, MG; Sheianov, MV; Shumilova, KM; Syrkin, AL, 2003)
"To compare the effects of carvedilol and metoprolol in preventing from left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats."	3.71	[Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats]. ( Chen, JL; Chen, ZJ; Gao, RL; Lu, SQ; Ruan, YM; Sun, RC; Tang, YD; Wang, PH; Yang, YJ; Zhang, P, 2001)
"Although carvedilol attenuates left ventricular (LV) remodeling in coronary occlusion-reperfusion, it is not known whether it attenuates ischemic LV remodeling because of coronary stenosis (CS) or permanent coronary occlusion (CO)."	3.71	Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. ( Maehara, K; Maruyama, Y; Sakabe, A; Yaoita, H, 2002)
"We sought to compare the effects of two different beta-blockers, carvedilol and metoprolol, to an angiotensin-converting enzyme (ACE) inhibitor (captopril) on myocardial collagen deposition during healing and ventricular remodeling after myocardial infarction (MI)."	3.70	Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. ( Chow, LT; Sanderson, JE; Wei, S, 2000)
"We administered oral metoprolol or no therapy to rats for 12 weeks after large myocardial infarction and subsequently examined left ventricular (LV) remodeling; myocardial tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 expression; and NO."	3.70	beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. ( Chandrasekar, B; Freeman, GL; Murray, DR; Prabhu, SD, 2000)
"Treatment with metoprolol of adults with chronic, moderate to severe AR had no effect on LV volumes."	2.82	Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. ( Aakhus, S; Broch, K; Fosså, K; Gullestad, L; Hopp, E; Lønnebakken, MT; Massey, R; Stueflotten, W; Urheim, S, 2016)
"In anterior STEMI patients undergoing primary angioplasty, the sooner IV metoprolol is administered in the course of infarction, the smaller the infarct and the higher the LVEF."	2.82	Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function. ( Aguero, J; Cabrera, JA; Fernández-Friera, L; Fernández-Jiménez, R; Fernández-Ortiz, A; Fuster, V; Galán-Arriola, C; García-Alvarez, A; García-Prieto, J; García-Ruiz, JM; Ibáñez, B; López-Martín, GJ; López-Melgar, B; Macías, A; Martínez-Tenorio, P; Mateos, A; Nuno-Ayala, M; Pérez-Asenjo, B; Pizarro, G; Sánchez-González, J, 2016)
"Beta-blocker therapy can ameliorate left ventricular remodeling in asymptomatic patients with left ventricular systolic dysfunction."	2.73	Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. ( Adams, KF; Armstrong, WF; Colucci, WS; Ghali, JK; Gottlieb, SS; Greenberg, B; Klibaner, MI; Kolias, TJ; Kukin, ML; Sugg, JE, 2007)
"In the metoprolol group, mitral regurgitation decreased (P=0."	2.71	Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiop ( Andersson, B; Böhm, M; Darius, M; Delius, W; Goss, F; Osterziel, KJ; Sigmund, M; Strömblad, O; Trenkwalder, SP; Waagstein, F; Wahlqvist, I, 2003)
"Treatment with ivabradine in patients within 2 years after HTX significantly reduced post-transplant heart rate and LV mass and was associated with a superior survival in comparison with patients receiving metoprolol succinate."	1.48	Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. ( Bruckner, T; Darche, FF; Doesch, AO; Ehlermann, P; Helmschrott, M; Katus, HA; Rahm, AK; Rivinius, R; Ruhparwar, A; Thomas, D, 2018)
"Metoprolol is a cardioprotective anti-hypertensive agent."	1.48	Modulation of cardiac stem cell characteristics by metoprolol in hypertensive heart disease. ( Nair, RR; Potnuri, AG; Saheera, S, 2018)
"Forty-two patients with idiopathic dilated cardiomyopathy treated with the therapy were studied."	1.37	Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. ( Doi, YL; Furuno, T; Hoshikawa, E; Kitaoka, H; Kubo, T; Matsumura, Y; Okawa, M; Takata, J; Yamasaki, N, 2011)
"Treatment with metoprolol decreased systolic blood pressure at 21 months only but improved survival, decreased ventricular weight, prevented chamber dilation, reduced inflammation, decreased fibrosis, attenuated action potential prolongation, improved systolic and diastolic function, decreased stiffness and improved endothelium-independent vascular responses."	1.37	Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat. ( Brown, L; Chan, V; Fenning, A; Hoey, A, 2011)
"Metoprolol treatment for 2 weeks improved LV systolic function."	1.35	Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009)
"Hypertension is associated with left ventricular hypertrophy (LVH) and diastolic dysfunction."	1.35	Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits. ( Bousquet, PP; Monassier, LJ; Signolet, IL, 2008)
"The treatment with metoprolol 1 mg/kg/h was initiated in the third week post-infarct for a period of 6 weeks."	1.32	Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. ( Bollano, E; Omerovic, E; Soussi, B; Waagstein, F, 2003)

Research

Studies (78)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Left Ventricular Ejection Fraction

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.28)	18.2507
2000's	41 (52.56)	29.6817
2010's	34 (43.59)	24.3611
2020's	2 (2.56)	2.80

Authors	Studies
Bogush, N	1
Tan, L	1
Naqvi, E	1
Calvert, JW	1
Graham, RM	1
Taylor, WR	1
Naqvi, N	1
Husain, A	1
Podlesnikar, T	1
Pizarro, G	2
Fernández-Jiménez, R	2
Montero-Cabezas, JM	1
Greif, N	1
Sánchez-González, J	2
Bucciarelli-Ducci, C	1
Marsan, NA	1
Fras, Z	1
Bax, JJ	1
Fuster, V	4
Ibáñez, B	4
Delgado, V	1
Dariolli, R	1
Naghetini, MV	1
Marques, EF	1
Takimura, CK	1
Jensen, LS	1
Kiers, B	1
Tsutsui, JM	1
Mathias, W	1
Lemos Neto, PA	1
Krieger, JE	1
Rivinius, R	1
Helmschrott, M	1
Ruhparwar, A	1
Rahm, AK	1
Darche, FF	1
Thomas, D	1
Bruckner, T	1
Ehlermann, P	1
Katus, HA	1
Doesch, AO	1
Saheera, S	2
Potnuri, AG	2
Nair, RR	2
Silvestre, OM	1
Farias, AQ	1
Ramos, DS	1
Furtado, MS	1
Rodrigues, AC	1
Ximenes, RO	1
de Campos Mazo, DF	1
Yoshimura Zitelli, PM	1
Diniz, MA	1
Andrade, JL	1
Strunz, C	1
Friedmann, AA	1
Lee, SS	1
Carrilho, FJ	1
D'Albuquerque, LAC	1
Bacal, F	1
Allakonda, L	1
Appavoo, A	1
Babick, A	1
Elimban, V	1
Zieroth, S	1
Dhalla, NS	1
Kaya, MG	1
Sarli, B	1
Akpek, M	1
Kaya, EG	1
Yarlioglues, M	1
Topsakal, R	1
Lam, YY	1
Liu, HB	1
Lin, CH	1
Zhou, GY	1
Chen, GZ	1
Cai, WY	1
Thireau, J	2
Karam, S	2
Roberge, S	2
Roussel, J	1
Aimond, F	2
Cassan, C	2
Gac, A	1
Babuty, D	2
Le Guennec, JY	1
Lacampagne, A	2
Fauconnier, J	2
Richard, S	2
Rizzi, E	1
Guimaraes, DA	1
Ceron, CS	1
Prado, CM	1
Pinheiro, LC	1
Martins-Oliveira, A	1
Gerlach, RF	1
Tanus-Santos, JE	1
Navaratnarajah, M	2
Siedlecka, U	2
Ibrahim, M	2
van Doorn, C	2
Soppa, G	1
Gandhi, A	2
Shah, A	2
Kukadia, P	1
Yacoub, MH	2
Terracciano, CM	2
Roolvink, V	1
Rasoul, S	1
Ottervanger, JP	1
Dambrink, JH	1
Lipsic, E	1
van der Horst, IC	1
de Smet, B	1
Kedhi, E	1
Marcel Gosselink, AT	1
Piek, JJ	1
Sanchez-Brunete, V	1
Van't Hof, AW	1
Ye, Y	1
Gong, H	1
Wang, X	1
Wu, J	1
Wang, S	1
Yuan, J	1
Yin, P	1
Jiang, G	1
Li, Y	4
Ding, Z	1
Zhang, W	1
Zhou, J	1
Ge, J	1
Zou, Y	1
Rinaldi, B	1
Donniacuo, M	2
Sodano, L	1
Gritti, G	1
Martuscelli, E	1
Orlandi, A	1
Rafaniello, C	1
Rossi, F	1
Calzetta, L	1
Capuano, A	1
Matera, MG	1
Li, W	1
Yan, S	1
Zhao, J	2
Ding, X	1
Zhang, S	1
Wang, D	2
Liu, L	2
Peng, W	1
Li, H	1
Liu, Z	1
Kelloniemi, A	1
Aro, J	1
Näpänkangas, J	1
Koivisto, E	1
Mustonen, E	1
Ruskoaho, H	2
Rysä, J	1
Broch, K	2
Urheim, S	2
Lønnebakken, MT	1
Stueflotten, W	2
Massey, R	2
Fosså, K	2
Hopp, E	2
Aakhus, S	2
Gullestad, L	2
Evangelista, A	1
Otto, CM	1
García-Ruiz, JM	1
García-Alvarez, A	1
Galán-Arriola, C	1
Fernández-Friera, L	1
Mateos, A	1
Nuno-Ayala, M	1
Aguero, J	1
García-Prieto, J	1
López-Melgar, B	1
Martínez-Tenorio, P	1
López-Martín, GJ	1
Macías, A	1
Pérez-Asenjo, B	1
Cabrera, JA	1
Fernández-Ortiz, A	1
Nazeri, A	1
Elayda, MA	1
Segura, AM	1
Stainback, RF	1
Nathan, J	1
Lee, VV	1
Bove, C	1
Sampaio, L	1
Grace, B	1
Massumi, A	1
Razavi, M	1
Rastogi, S	3
Sharov, VG	3
Mishra, S	3
Gupta, RC	3
Blackburn, B	1
Belardinelli, L	1
Stanley, WC	2
Sabbah, HN	3
Zacà, V	1
Wang, M	1
Goldstein, S	1
Pat, B	1
Killingsworth, C	1
Denney, T	2
Zheng, J	1
Powell, P	1
Tillson, M	1
Dillon, AR	1
Dell'Italia, LJ	3
Rengo, G	1
Lymperopoulos, A	1
Zincarelli, C	1
Soltys, S	1
Rabinowitz, JE	1
Koch, WJ	1
Zheng, X	1
Chen, S	1
Wang, J	2
Yang, T	1
Chen, Y	1
Serpi, R	1
Tolonen, AM	1
Tenhunen, O	1
Pieviläinen, O	1
Kubin, AM	1
Vaskivuo, T	1
Soini, Y	1
Kerkelä, R	1
Leskinen, H	1
Remme, WJ	1
Vanzelli, AS	1
Medeiros, A	1
Sirvente, Rde A	1
Salemi, VM	1
Mady, C	1
Brum, PC	1
Cimmino, G	1
Giannarelli, C	1
Prat-González, S	1
Hutter, R	1
Garcia, M	1
Sanz, J	1
Badimon, JJ	1
Hoshikawa, E	1
Matsumura, Y	1
Kubo, T	1
Okawa, M	1
Yamasaki, N	1
Kitaoka, H	1
Furuno, T	1
Takata, J	1
Doi, YL	1
Fang, Y	1
Nicol, L	1
Harouki, N	1
Monteil, C	1
Wecker, D	1
Debunne, M	1
Bauer, F	1
Lallemand, F	1
Richard, V	1
Thuillez, C	1
Mulder, P	1
Chan, V	1
Fenning, A	1
Hoey, A	1
Brown, L	1
Shi, J	1
Yang, BF	1
Han, CL	1
Li, WM	2
Dong, DL	1
Pan, ZW	1
Liu, GZ	1
Geng, JQ	1
Sheng, L	1
Tan, XY	1
Sun, DH	1
Gong, ZH	1
Gong, YT	1
Chen, B	1
Jiang, S	1
Xie, YP	1
Guo, A	1
Kutschke, W	1
Zimmerman, K	1
Weiss, RM	1
Miller, FJ	1
Anderson, ME	1
Song, LS	1
Becher, PM	1
Lindner, D	1
Miteva, K	1
Savvatis, K	1
Zietsch, C	1
Schmack, B	1
Van Linthout, S	1
Westermann, D	1
Schultheiss, HP	1
Tschöpe, C	1
Cazorla, O	1
Ahmed, MI	1
Aban, I	1
Lloyd, SG	1
Gupta, H	1
Howard, G	1
Inusah, S	1
Peri, K	1
Robinson, J	1
Smith, P	1
McGiffin, DC	1
Schiros, CG	1
Dias, P	1
Sarathchandra, P	1
Groenning, BA	2
Nilsson, JC	2
Hildebrandt, PR	2
Kjaer, A	1
Fritz-Hansen, T	2
Larsson, HB	2
Sondergaard, L	2
Bertaglia, E	1
D'Este, D	1
Zerbo, F	1
Michieletto, M	1
Pascotto, P	1
Syrkin, AL	1
Poltavskaia, MG	1
Shumilova, KM	1
Ivanov, GG	1
Churganova, LIu	1
Sheianov, MV	1
Gavril'eva, SA	1
Tang, YD	1
Yang, YJ	1
Zhang, P	1
Ruan, YM	1
Lu, SQ	1
Sun, RC	1
Wang, PH	1
Gao, RL	1
Chen, JL	1
Chen, ZJ	1
McKelvie, RS	1
Rouleau, JL	1
White, M	1
Afzal, R	1
Young, JB	1
Maggioni, AP	1
Held, P	1
Yusuf, S	1
Waagstein, F	2
Strömblad, O	1
Andersson, B	1
Böhm, M	1
Darius, M	1
Delius, W	1
Goss, F	1
Osterziel, KJ	1
Sigmund, M	1
Trenkwalder, SP	1
Wahlqvist, I	1
Omerovic, E	1
Bollano, E	1
Soussi, B	1
Yang, Y	1
Tang, Y	1
Ruan, Y	1
Wang, Y	1
Gao, R	1
Chen, J	1
Chen, Z	1
Udelson, JE	1
Plante, E	2
Lachance, D	2
Gaudreau, M	1
Drolet, MC	2
Roussel, E	2
Arsenault, M	2
Couet, J	2
Kobayashi, M	1
Machida, N	1
Mitsuishi, M	1
Yamane, Y	1
Cinquegrana, G	1
D'Aniello, L	1
Landi, M	1
Spinelli, L	1
Grande, G	1
De Prisco, F	1
Petretta, M	1
Sun, YL	1
Hu, SJ	1
Wang, LH	1
Hu, Y	1
Zhou, JY	1
Williams, RE	1
Ahmet, I	2
Lakatta, EG	2
Talan, MI	2
Yan, SH	1
Hu, HS	1
Wang, XL	1
Xing, QC	1
Wang, Q	1
Shi, CW	1
Cheng, WJ	1
Xue, M	1
Miao, GB	1
Liu, JC	1
Liu, MB	1
Wu, JL	1
Zhang, G	1
Chang, J	1
Zhang, L	1
Laviolle, B	1
Pape, D	1
Turlin, B	1
Bellissant, E	1
Cheng, Y	1
George, I	1
Yi, GH	1
Reiken, S	1
Gu, A	1
Tao, YK	1
Muraskin, J	1
Qin, S	1
He, KL	1
Hay, I	1
Yu, K	1
Oz, MC	1
Burkhoff, D	2
Holmes, J	1
Zhao, Q	1
Wu, TG	1
Jiang, ZF	1
Chen, GW	1
Lin, Y	1
Wang, LX	1
Imai, M	1
Mika, Y	1
Rousso, B	1
Ben-Haim, S	1
Colucci, WS	1
Kolias, TJ	1
Adams, KF	1
Armstrong, WF	1
Ghali, JK	1
Gottlieb, SS	1
Greenberg, B	1
Klibaner, MI	1
Kukin, ML	1
Sugg, JE	1
Qu, XF	1
Zhao, CY	1
Cao, FL	1
Zhou, T	1
Huang, YL	1
Signolet, IL	1
Bousquet, PP	1
Monassier, LJ	1
Krawczyk, M	1
Zhu, W	1
Woo, AY	1
Morrell, C	1
Poosala, S	1
Xiao, RP	1
Champetier, S	1
Maczewski, M	1
Mackiewicz, U	1
Gourine, A	1
Bondar, SI	1
Spyer, KM	1
Gourine, AV	1
Sabri, A	1
Rafiq, K	1
Seqqat, R	1
Kolpakov, MA	1
Dillon, R	1
Kramer, CM	1
Nicol, PD	1
Rogers, WJ	1
Seibel, PS	1
Park, CS	1
Reichek, N	1
Prabhu, SD	1
Chandrasekar, B	1
Murray, DR	1
Freeman, GL	1
Wei, S	1
Chow, LT	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
"Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The MEEffect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion (METOCARD-CNIC): A Randomized, Controlled Parallel-group, Observer-blinded Clinical Trial[NCT01311700]	Phase 4	221 participants (Actual)	Interventional	2010-11-30	Completed
Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation[NCT01157572]	Phase 4	75 participants (Actual)	Interventional	2010-08-31	Completed
Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428]	Phase 2/Phase 3	38 participants (Actual)	Interventional	2004-08-31	Completed
Italian Registry on Cardiac Contractility Modulation Therapy[NCT04327323]		200 participants (Anticipated)	Observational [Patient Registry]	2019-09-01	Recruiting
[NCT00038077]	Phase 3	300 participants	Interventional	2001-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Left Ventricular End Diastolic Volume Indexed to Body Surface Area

Intervention	percent (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,1)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	62.62	63.90	63.80	41.90	61.70	44.70	60.95	53.79	59.95
Toprol XL	62.09	NA	61.29	54.81	62.77	68.47	62.05	NA	63.02

Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Left Ventricular End Systolic Volume Indexed to Body Surface Area

Intervention	ml/m^2 (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,0)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	91.66	90.93	90.84	70.56	88.99	82.73	90.16	85.75	87.31
Toprol XL	95.74	NA	95.24	NA	95.71	98.16	97.6	NA	95.16

Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume

Intervention	ml/m^2 (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,0)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	34.01	32.83	32.53	40.99	33.70	47.25	34.99	39.97	34.47
Toprol XL	35.98	NA	36.53	NA	35.89	30.97	36.72	NA	35.13

Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Left Ventricular End-Diastolic Radius to Wall Thickness

Intervention	g/ml (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,1)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	0.61	0.53	0.62	0.67	0.65	0.65	0.65	0.61	0.64
Toprol XL	0.61	NA	0.6	0.53	0.60	0.55	0.59	NA	0.62

Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Peak Early Filling Rate: Rate of Change Over Time

Intervention	unitless (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,1)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	4.76	5.02	4.51	4.15	4.46	4.61	4.43	4.72	4.52
Toprol XL	4.69	NA	4.85	5.74	4.79	5.02	4.77	NA	4.59

Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Systolic Longitudinal Strain

Intervention	EDV/sec (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,0)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	2.27	2.58	2.38	1.56	2.26	1.83	1.95	1.73	2.17
Toprol XL	2.12	NA	2.08	NA	2.24	2.28	2.26	NA	2.25

Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)

Intervention	percent/%Systolic interval (Mean)
	Month 0 (n=19,19)	Month 3 (n=1,0)	Month 6 (n=17,19)	Month 9 (n=1,0)	Month 12 (n=14,15)	Month 15 (n=3,2)	Month 18 (n=14,18)	Month 21 (n=5,0)	Month 24 (n=16,18)
Placebo	87.94	115.07	45.90	37.2	87.85	52.95	88.11	67.53	79.94
Toprol XL	82.55	NA	78.68	NA	80.04	88.34	79.29	NA	85.18

Article	Year
Ventricular remodeling in heart failure and the effect of beta-blockade. The American journal of cardiology, 2004, May-06, Volume: 93, Issue:9A Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Metoprolol; Propanolamin	2004
Early initiation of beta blockade in heart failure: issues and evidence. Journal of clinical hypertension (Greenwich, Conn.), 2005, Volume: 7, Issue:9 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol	2005

Article	Year
Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy). Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2020, 06-11, Volume: 22, Issue:1 Topics: Administration, Intravenous; Adrenergic beta-1 Receptor Antagonists; Aged; Anterior Wall Myocardial	2020
β-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:8 Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Biomarkers; Brazil; Cardiac Output; Cardi	2018
Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol. Cardiology journal, 2014, Volume: 21, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Biomarkers; Carbazoles; Cardiomyopathy, Dilate	2014
Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention: EAR American heart journal, 2014, Volume: 168, Issue:5 Topics: Administration, Intravenous; Adrenergic beta-Antagonists; Combined Modality Therapy; Double-Blind Me	2014
Controlled release metoprolol for aortic regurgitation: a randomised clinical trial. Heart (British Cardiac Society), 2016, Volume: 102, Issue:3 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aortic Valve Insufficiency; Asymptomatic Diseases; De	2016
Impact of the Timing of Metoprolol Administration During STEMI on Infarct Size and Ventricular Function. Journal of the American College of Cardiology, 2016, May-10, Volume: 67, Issue:18 Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Disease Models, Animal; Drug Administration Schedul	2016
A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. Journal of the American College of Cardiology, 2012, Aug-28, Volume: 60, Issue:9 Topics: Adrenergic beta-Antagonists; Adult; Aged; Case-Control Studies; Female; Humans; Magnetic Resonance I	2012
Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. European journal of heart failure, 2002, Volume: 4, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Biological Factors; Biomarkers; Blood P	2002
Effects of verapamil and metoprolol on recovery from atrial electrical remodeling after cardioversion of long-lasting atrial fibrillation. International journal of cardiology, 2003, Volume: 87, Issue:2-3 Topics: Aged; Analysis of Variance; Atrial Fibrillation; Atrial Function; Calcium Channel Blockers; Echocard	2003
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. European heart journal, 2003, Volume: 24, Issue:19 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	2003
Increased exercise ejection fraction and reversed remodeling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiop European journal of heart failure, 2003, Volume: 5, Issue:5 Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Double-Blind Method; Exercise; Exercise Test;	2003
Effects of different degrees of sympathetic antagonism on cytokine network in patients with ischemic dilated cardiomyopathy. Journal of cardiac failure, 2005, Volume: 11, Issue:3 Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Echocardiography; Fema	2005
Early initiation of beta blockade in heart failure: issues and evidence. Journal of clinical hypertension (Greenwich, Conn.), 2005, Volume: 7, Issue:9 Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Heart Failure; Humans; Hypertension; Metoprolol	2005
Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation, 2007, Jul-03, Volume: 116, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting E	2007
Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:7 Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Heart Fail	2000
Effect of early treatment with captopril and metoprolol singly and together on postinfarction left ventricular remodeling. American heart journal, 2001, Volume: 142, Issue:4 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Comb	2001

Article	Year
Remuscularization with triiodothyronine and β Scientific reports, 2022, 05-25, Volume: 12, Issue:1 Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Metoprolol; Mice; Myocardial Infarction; Myocardium	2022
Allogeneic pASC transplantation in humanized pigs attenuates cardiac remodeling post-myocardial infarction. PloS one, 2017, Volume: 12, Issue:4 Topics: Adipose Tissue; Animals; Coronary Circulation; Enalaprilat; Female; Hemodynamics; Mesenchymal Stem C	2017
Control of cardiac chronotropic function in patients after heart transplantation: effects of ivabradine and metoprolol succinate on resting heart rate in the denervated heart. Clinical research in cardiology : official journal of the German Cardiac Society, 2018, Volume: 107, Issue:2 Topics: Adult; Anti-Arrhythmia Agents; Benzazepines; Female; Germany; Heart; Heart Rate; Heart Transplantati	2018
Modulation of cardiac stem cell characteristics by metoprolol in hypertensive heart disease. Hypertension research : official journal of the Japanese Society of Hypertension, 2018, Volume: 41, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Cardiomegaly; Cell Movement; Cell Proliferatio	2018
Association of histamine with hypertension-induced cardiac remodeling and reduction of hypertrophy with the histamine-2-receptor antagonist famotidine compared with the beta-blocker metoprolol. Hypertension research : official journal of the Japanese Society of Hypertension, 2018, Volume: 41, Issue:12 Topics: Adrenergic beta-1 Receptor Antagonists; Age Factors; Animals; Blood Pressure; Cardiomegaly; Famotidi	2018
Reversal of cardiac dysfunction and subcellular alterations by metoprolol in heart failure due to myocardial infarction. Journal of cellular physiology, 2013, Volume: 228, Issue:10 Topics: Adenosine Triphosphatases; Animals; Calcium; Calcium-Binding Proteins; Cardiac Output; Dopamine; Epi	2013
Effect of Xinjikang on left ventricular hypertrophy remodeling in hypertensive rats. Asian Pacific journal of tropical medicine, 2013, Volume: 6, Issue:12 Topics: Animals; Antihypertensive Agents; Blood Pressure; Drugs, Chinese Herbal; Female; Hypertension; Male;	2013
Β-adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure? Heart (British Cardiac Society), 2014, Volume: 100, Issue:11 Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dose-Response Re	2014
β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy. Free radical biology & medicine, 2014, Volume: 73 Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzopyrans;	2014
Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading. PloS one, 2014, Volume: 9, Issue:9 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Calcium; Clenb	2014
Combination Treatment With Antihypertensive Agents Enhances the Effect of Qiliqiangxin on Chronic Pressure Overload-induced Cardiac Hypertrophy and Remodeling in Male Mice. Journal of cardiovascular pharmacology, 2015, Volume: 65, Issue:6 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme	2015
Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. British journal of pharmacology, 2015, Volume: 172, Issue:14 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Blood Pressure	2015
Metoprolol Inhibits Cardiac Apoptosis and Fibrosis in a Canine Model of Chronic Obstructive Sleep Apnea. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, Volume: 36, Issue:3 Topics: Actins; Animals; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; bcl-Associated De	2015
TSC-22 up-regulates collagen 3a1 gene expression in the rat heart. BMC cardiovascular disorders, 2015, Oct-13, Volume: 15 Topics: Animals; Antihypertensive Agents; Cells, Cultured; Collagen Type III; Female; Gene Expression; Gene	2015
Medical treatment for chronic aortic regurgitation: β-blockers--maybe not bad, but good? Heart (British Cardiac Society), 2016, Volume: 102, Issue:3 Topics: Adrenergic beta-1 Receptor Antagonists; Aortic Valve Insufficiency; Female; Humans; Male; Metoprolol	2016
Heartbeat: Beta-blockers for aortic regurgitation. Heart (British Cardiac Society), 2016, Volume: 102, Issue:3 Topics: Adrenergic beta-1 Receptor Antagonists; Aortic Valve Insufficiency; Female; Humans; Male; Metoprolol	2016
Exercise capacity and peak oxygen consumption in asymptomatic patients with chronic aortic regurgitation. International journal of cardiology, 2016, Nov-15, Volume: 223 Topics: Adolescent; Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Aortic Valve Insufficiency; Asympto	2016
Comparative Efficacy of Nebivolol and Metoprolol to Prevent Tachycardia-Induced Cardiomyopathy in a Porcine Model. Texas Heart Institute journal, 2016, Volume: 43, Issue:6 Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Cardiac Pacing, Artificial; Cardiomyopathies; Disea	2016
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 295, Issue:5 Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardio	2008
Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure. Cardiology, 2009, Volume: 112, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Disease Models, Animal; Dogs; Drug Therapy, Combinat	2009
Dissociation between cardiomyocyte function and remodeling with beta-adrenergic receptor blockade in isolated canine mitral regurgitation. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 295, Issue:6 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Anima	2008
Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation, 2009, Jan-06, Volume: 119, Issue:1 Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Catecholamines; Chronic Disease; Dependovirus; Di	2009
Dilated cardiomyopathy with hypertension: prevalence and response to high-dose β1-adrenoceptor antagonist therapy. Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:9 Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Analysis of Variance; Antihypertensive Agents; Blood	2009
Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. Clinical and translational science, 2009, Volume: 2, Issue:6 Topics: Animals; Antihypertensive Agents; Apoptosis; Cell Count; Cell Proliferation; Heart Ventricles; Inter	2009
Which beta-blocker is most effective in heart failure? Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Adrenergic beta-Antagonists; Animals; Benzopyrans; Bisoprolol; Carbazoles; Carvedilol; Clinical Tria	2010
Association of physical training with beta-blockers in heart failure in mice. Arquivos brasileiros de cardiologia, 2010, Volume: 95, Issue:3 Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Carbazoles; Carvedilol; Collagen; Combin	2010
Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. International journal of cardiology, 2011, Dec-15, Volume: 153, Issue:3 Topics: Animals; Biomarkers; Carbazoles; Carvedilol; Down-Regulation; Metoprolol; Myocardial Infarction; Pro	2011
Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy. The American journal of cardiology, 2011, Apr-01, Volume: 107, Issue:7 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve	2011
Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol. Journal of molecular and cellular cardiology, 2011, Volume: 51, Issue:2 Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Benzopyrans; Disease Models, Animal; Endothelium, V	2011
Chronic β-adrenoceptor antagonist treatment controls cardiovascular remodeling in heart failure in the aging spontaneously hypertensive rat. Journal of cardiovascular pharmacology, 2011, Volume: 58, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Aging; Animals; Blood Pressure; Disease Models, Animal; Dose	2011
Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol. British journal of pharmacology, 2012, Volume: 165, Issue:6 Topics: Analgesics; Animals; Apoptosis; Apoptosis Inducing Factor; Fibrosis; Heart Ventricles; Illicit Drugs	2012
β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012, Volume: 26, Issue:6 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Caveolin 3; Male; Membrane Proteins; M	2012
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. Hypertension (Dallas, Tex. : 1979), 2012, Volume: 59, Issue:5 Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nuc	2012
Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. Cardiovascular research, 2012, Jul-01, Volume: 95, Issue:1 Topics: Animals; Arrhythmias, Cardiac; Calcium; Electrocardiography; Heart Failure; Male; Metoprolol; Mice;	2012
Influence of ivabradine on reverse remodelling during mechanical unloading. Cardiovascular research, 2013, Feb-01, Volume: 97, Issue:2 Topics: Animals; Atrophy; Benzazepines; Calcium; Calcium Channels, L-Type; Excitation Contraction Coupling;	2013
[Effect of metoprolol CR/XL on remodeling of the heart and cardiac rhythm disturbances after myocardial infarction in patients with chronic heart failure]. Kardiologiia, 2003, Volume: 43, Issue:6 Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Female; Heart	2003
[Comparative effects of carvedilol and metoprolol in preventing from left ventricular remodeling after acute myocardial infarction in rats]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2001, Volume: 23, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Female; Metoprolol; Myocardial Infarct	2001
Selective beta1-blockade attenuates post-infarct remodelling without improvement in myocardial energy metabolism and function in rats with heart failure. European journal of heart failure, 2003, Volume: 5, Issue:6 Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Disease Models, Animal; Echocardiography	2003
Comparison of metoprolol with low, middle and high doses of carvedilol in prevention of postinfarction left ventricular remodeling in rats. Japanese heart journal, 2003, Volume: 44, Issue:6 Topics: Animals; Carbazoles; Cardiac Volume; Carvedilol; Dose-Response Relationship, Drug; Female; Heart Rat	2003
Effectiveness of beta-blockade in experimental chronic aortic regurgitation. Circulation, 2004, Sep-14, Volume: 110, Issue:11 Topics: Adrenergic beta-Antagonists; Animals; Aortic Valve Insufficiency; Catecholamines; Cell Size; Chronic	2004
Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. American journal of hypertension, 2004, Volume: 17, Issue:12 Pt 1 Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Dopp	2004
Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest, 2005, Volume: 128, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Carbaz	2005
Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. Heart failure reviews, 2005, Volume: 10, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta	2005
Effects of prolonged metoprolol treatment on neural remodeling and inducible ventricular arrhythmias after myocardial infarction in rabbits. International journal of cardiology, 2007, May-02, Volume: 117, Issue:3 Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Heart Ventricles; Metoprolol; Myocardial	2007
Autoantibody against beta1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment. European journal of clinical investigation, 2006, Volume: 36, Issue:9 Topics: Adrenergic beta-Antagonists; Autoantibodies; Drug Administration Schedule; Exercise Test; Female; He	2006
Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters. Journal of cardiac failure, 2006, Volume: 12, Issue:9 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dila	2006
Bradycardic therapy improves left ventricular function and remodeling in dogs with coronary embolization-induced chronic heart failure. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:2 Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Coronary Stenosis; Dogs; Echocardiograp	2007
Effect of beta-blockers on beta3-adrenoceptor expression in chronic heart failure. Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:2 Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Gene	2007
Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. Journal of the American College of Cardiology, 2007, May-29, Volume: 49, Issue:21 Topics: Adrenergic beta-Antagonists; Animals; Defibrillators, Implantable; Disease Models, Animal; Dogs; Ele	2007
Effects of metoprolol treatment on a disintegrin metalloproteinase expression and extracellular matrix remodeling after myocardial infarction in rats. Chinese medical journal, 2007, Sep-05, Volume: 120, Issue:17 Topics: ADAM Proteins; ADAM17 Protein; Adrenergic beta-Antagonists; Animals; Male; Metoprolol; Myocardial In	2007
Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits. American journal of hypertension, 2008, Volume: 21, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Cardiomyopathies; Dia	2008
Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 325, Issue:2 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonist	2008
Benefits of long-term beta-blockade in experimental chronic aortic regurgitation. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:4 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta	2008
Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovascular research, 2008, Jul-01, Volume: 79, Issue:1 Topics: Adrenergic beta-Antagonists; Animals; Benzazepines; Calcium; Disease Models, Animal; Heart Failure;	2008
Beneficial effect of the central nervous system beta-adrenoceptor blockade on the failing heart. Circulation research, 2008, Mar-28, Volume: 102, Issue:6 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Brain; Disease Models,	2008
Sympathetic activation causes focal adhesion signaling alteration in early compensated volume overload attributable to isolated mitral regurgitation in the dog. Circulation research, 2008, May-09, Volume: 102, Issue:9 Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Apoptosis; Cells, Cult	2008
Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling. The American journal of physiology, 1999, Volume: 277, Issue:4 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Female; Heart Conduc	1999
beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation, 2000, May-02, Volume: 101, Issue:17 Topics: Adrenergic beta-Antagonists; Animals; Cytokines; Gene Expression; Interleukin-1; Interleukin-6; Isop	2000
Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:1 Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carbazoles; Carvedil	2000
Different effects of carvedilol, metoprolol, and propranolol on left ventricular remodeling after coronary stenosis or after permanent coronary occlusion in rats. Circulation, 2002, Feb-26, Volume: 105, Issue:8 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Ascorbic Acid; Carbazoles; Cardi	2002
Myocardial oxidative metabolism in remote normal regions in the left ventricles with remodeling after myocardial infarction: effect of beta-adrenoceptor blockers. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002, Volume: 43, Issue:6 Topics: Acetates; Adrenergic beta-Antagonists; Atenolol; Carbon Radioisotopes; Cardiac Catheterization; Case	2002

metoprolol and Cardiac Remodeling, Ventricular